BenzingaSeptember 1, 2026 at 8:11 AM NY3 days ago
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273
Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Exploring the top movers within the S&P500 index during today's session.
ChartMill44 minutes ago
Sector Update: Financial
Yahoo2 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo2 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill2 hours ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill3 hours ago